Piper Sandler lowered the firm’s price target on Arvinas (ARVN) to $24 from $67 on narrowed vepdegestrant ESR1-mutant mBC approval, while ...

Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ...

fulvestrant in 2nd-line ESR1-mutant ER+/HER2- mBC patients. Arvinas and Pfizer (PFE) will present data at a medical meeting and submit regulatory filings, which could lead to approval in 2026.

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where ...

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

Also Read: Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial The trial also showed an encouraging safety/tolerability profile and favorable ...

Pfizer is already active in the protein degrader area, having partnered with Arvinas in a $2 billion-plus deal signed in 2021 focusing on vepdegestrant (ARV-471), an orally active selective ...

Pfizer isn't a great pick for growth investors, although its growth prospects are better than some might think. The stock is a good fit for value investors, though, with its low forward earnings ...